Background: The influence of the duration of anticoagulant therapy after venous
thromboembolism (VTE) on the long‐term morbidity and mortality is unclear. Aim: To …

Introduction Venous thromboembolism (VTE) carries a considerable risk of recurrence and
anticoagulants should be administered for a minimum of three months. Since little is known …

Background The long‐term risk for recurrent venous thromboembolism (VTE) during
extended anticoagulation for a first unprovoked VTE is uncertain. Objectives To determine …

Background: The risk of recurrence is lower after treatment of an episode of venous
thromboembolism associated with a transient risk factor, such as recent surgery, than after …

Background: About 30% of patients with an episode of adequately treated deep venous
thrombosis (DVT) develop the postthrombotic syndrome (PTS) within 2 years. During …

Abstract Background and Objectives While it has long been recognized that patients with
acute unprovoked deep vein thrombosis (DVT) or pulmonary embolism (PE) have a higher …

ContextPatients with venous thromboembolism (VTE) are susceptible to recurrent events,
but whether prolonging anticoagulation is warranted in patients with VTE remains …

Long-term treatment of venous thromboembolism (VTE) focuses mainly on the duration of
anticoagulant therapy, usually with vitamin K (VK) antagonists. The duration of therapy …

Pinede L, Duhaut P, Cucherat M, Ninet J, Pasquier J, Boissel JP (Hôpital Edouard Herriot
and Unité de Pharmacologie Clinique, Lyon, France). J Intern Med 2000; 247: 553–562 …

Objectives To determine the rate of a first recurrent venous thromboembolism (VTE) event
after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked …